AB928
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for AB928, covering 2024-05-17 to 2025-08-27. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. [Phase 2]